Skip to main content


Figure 6 | Genetic Vaccines and Therapy

Figure 6

From: Characterization of a potent non-cytotoxic shRNA directed to the HIV-1 co-receptor CCR5

Figure 6

shRNA CCR5 (1005) inhibit R5 tropic HIV-1 replication in PBMCs. CD8+ cells depleted PBMCs were activated with PHA for 2 days. Cells were transduced with either shRNA CCR5 (1005) expressing vector or non-shRNA control vector (FG11F). Vector transduced cells were cultured in IL-2 containing medium and infected with either R5 tropic reporter HIV-1NFNSXHSA (A). After 3 days infection, cells were harvested and examined for CCR5 expression in EGFP+ vector transduced population in the upper panel, and HSA expression in EGFP+ vector transduced population by flow cytometry.

Back to article page